公开(公告)号：US08124093B2

公开(公告)日：2012-02-28

申请号：US12503822

申请日：2009-07-15

Applicant: Antonio Lanzavecchia ,  Annalisa Macagno

Inventor： Antonio Lanzavecchia ,  Annalisa Macagno

IPC: A61K39/42 ,  A61K39/395 ,  A61K39/00 ,  A61K39/25 ,  C12P21/08 ,  C07K15/00

CPC classification number: C07K16/088 ,  A01D34/63 ,  A01D34/71 ,  A01D2101/00 ,  A61K38/00 ,  A61K39/00 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/005 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92 ,  C12N2710/16122

Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.

公开(公告)号：US07048938B2

公开(公告)日：2006-05-23

申请号：US10793232

申请日：2004-03-04

Applicant: Kanaiyalal R. Patel ,  Yunhua N. Jeng

Inventor： Kanaiyalal R. Patel ,  Yunhua N. Jeng

IPC: C07K15/00

CPC classification number: A61K38/27 ,  A61K9/0019 ,  A61K47/02 ,  A61K47/18 ,  A61K47/183 ,  A61K47/26 ,  A61K47/44

Abstract: The present invention provides compositions which allow for the extended release and enhanced bioavailability of biologically-active polypeptides following parenteral delivery to an animal. More particularly, it concerns compositions comprising biologically-active somatotropin formulated for extended release, methods of preparing these compositions, and methods of using the same. These compositions comprise somatotropin, a bioavailability-enhancing constituent (BEC), and a substantially non-aqueous, hydrophobic excipient. The BEC may comprise (i) amino acids or amino acid derivatives, such as histidine-HCl; (ii) hydroxamate derivatives, such as histidine hydroxamate or suberohydroxamic acid; (iii) non-reducing carbohydrates, such as trehalose or trehalose octaacetate; (iv) oxo-acid salts, such as a mixture of monobasic and dibasic sodium phosphate; or (v) a mixture of two or more compounds from within the foregoing classes (i)–(iv).

Abstract translation: 本发明提供了允许在肠胃外输送到动物后的生物活性多肽的延长释放和增强的生物利用度的组合物。 更具体地，涉及包含用于延长释放的生物活性生长激素配制剂，制备这些组合物的方法和使用该组合物的方法的组合物。 这些组合物包含生长激素，生物利用度增加成分（BEC）和基本上非水性的疏水性赋形剂。 BEC可以包含（i）氨基酸或氨基酸衍生物，例如组氨酸-HCl; （ii）异羟肟酸衍生物，例如羟肟酸组氨酸或苏泊酸肟酸; （iii）非还原性碳水化合物，例如海藻糖或海藻糖八乙酸酯; （iv）含氧酸盐，例如一元和二元磷酸钠的混合物; 或（v）来自上述（i） - （iv）类的两种或更多种化合物的混合物。

公开(公告)号：US6166184A

公开(公告)日：2000-12-26

申请号：US912778

申请日：1997-08-18

Applicant: Marc Hendriks ,  Verhoeven Michel ,  Patrick Cahalan ,  Mark W. Torrianni ,  Linda Cahalan ,  Benedicte Fouache

Inventor： Marc Hendriks ,  Verhoeven Michel ,  Patrick Cahalan ,  Mark W. Torrianni ,  Linda Cahalan ,  Benedicte Fouache

IPC: A61L27/36 ,  C08H1/06 ,  C07K13/00 ,  C07K15/00

CPC classification number: A61L27/3687 ,  C08H1/06

Abstract: Methods for making bioprosthetic devices made of collagen-based material having collagen amine groups and collagen carboxyl groups are provided. The methods include blocking at least a portion of the collagen amine groups with a blocking agent, activating at least a portion of the collagen carboxyl groups after blocking at least a portion of the collagen amine groups to form activated carboxyl groups, and contacting the activated collagen carboxyl groups with a polyfunctional spacer to crosslink the collagen-based material.

Abstract translation: 提供用于制造具有胶原胺基和胶原羧基的胶原基材料制成生物假体装置的方法。 所述方法包括用封闭剂封闭至少一部分胶原胺基团，在封闭至少一部分胶原胺基团以形成活化的羧基之后激活至少一部分胶原羧基，并使活化的胶原 羧基与多官能间隔基交联胶原基材料。

公开(公告)号：US6162789A

公开(公告)日：2000-12-19

申请号：US385135

申请日：1999-08-30

Applicant: Peter John Lillford ,  Andrew John McArthur ,  Christopher Michael Sidebottom ,  Peter Wilding

Inventor： Peter John Lillford ,  Andrew John McArthur ,  Christopher Michael Sidebottom ,  Peter Wilding

IPC: A23G9/32 ,  A23G9/38 ,  A23G9/42 ,  A23G9/44 ,  A23G9/52 ,  A23J1/00 ,  A23L3/36 ,  A23L3/37 ,  C07K14/415 ,  C12N15/09 ,  C12N15/29 ,  C12N15/82 ,  C12P21/02 ,  A61K38/00 ,  A61K38/02 ,  C07K5/00 ,  C07K7/00 ,  C07K15/00

CPC classification number: A23G9/38 ,  A23G9/42 ,  A23G9/52 ,  A23G2200/10 ,  A23G2200/14 ,  A23J1/007 ,  C07K14/415 ,  C12N15/8273

Abstract: A process for the recovery of AFPs from natural sources, said process involving the steps ofa) isolating an AFP containing juice from the natural source;b) heat treating the natural source or the AFP containing juice to a temperature of at least 60.degree. C.;c) removing the insoluble fraction.

Abstract translation: 一种从天然来源回收AFP的方法，所述方法包括以下步骤：a）将含有AFP的果汁从天然来源中分离出来; b）将天然来源或含有AFP的汁液热处理至至少60℃的温度; c）除去不溶性部分。

公开(公告)号：US5889148A

公开(公告)日：1999-03-30

申请号：US700449

申请日：1996-08-27

Applicant: Keun-Hyeung Lee ,  Sung-Yu Hong ,  Hyun-Sook Cho ,  Bok-Leul Lee ,  Kwang-Hoe Chung ,  Jeong-Hyeok Yoon ,  Jong-Eun Oh ,  Hong-Mo Moon

Inventor： Keun-Hyeung Lee ,  Sung-Yu Hong ,  Hyun-Sook Cho ,  Bok-Leul Lee ,  Kwang-Hoe Chung ,  Jeong-Hyeok Yoon ,  Jong-Eun Oh ,  Hong-Mo Moon

IPC: A61K38/00 ,  A61P31/04 ,  C07K14/435 ,  C07K5/00 ,  C07K7/00 ,  C07K15/00

CPC classification number: C07K14/43563 ,  A61K38/00

Abstract: The present invention relates to novel antibiotic peptides which possess antibacterial and/or antifungal activities causing no cytotoxicity, and to antibacterial and/or antifungal agents containing said peptides as active ingredients. In accordance with the present invention, it has been discovered that a number of chemically-synthesized peptides which are derived from Tenecin, show superior antibacterial and/or antifungal activities, while causing no untoward effects, and they can be applied for the development of antibacterial and/or antifungal agents.

Abstract translation: PCT No.PCT / KR96 / 00034 Sec。 371日期：1996年8月27日 102（e）日期1996年8月27日PCT 1996年3月11日PCT公布。 出版物WO97 / 02286 日期1997年1月23日本发明涉及具有不引起细胞毒性的抗细菌和/或抗真菌活性的新型抗生素肽以及含有所述肽作为活性成分的抗细菌剂和/或抗真菌剂。 根据本发明，已经发现，从Tenecin衍生的多种化学合成的肽显示出优异的抗菌和/或抗真菌活性，同时不会产生不利影响，并且它们可用于开发抗菌剂 和/或抗真菌剂。

公开(公告)号：US5767236A

公开(公告)日：1998-06-16

申请号：US387634

申请日：1995-02-13

Applicant: Sun Hyuk Kim ,  Jacques-Pierre Moreau

Inventor： Sun Hyuk Kim ,  Jacques-Pierre Moreau

IPC: A61K38/00 ,  C07K7/08 ,  C07K5/00 ,  C07K7/00 ,  C07K15/00

CPC classification number: C07K7/086 ,  A61K38/00

Abstract: The invention features linear therapeutic peptides of the following formula: ##STR1## in which A.sup.1 is a D-.alpha.-aromatic amino acid or a D-.alpha.-tethered amino acid; A.sup.2 is Gln, His, 1-methyl-His, or 3-methyl-His; A.sup.3 is the D- or L-isomer selected from Nal, Trp, Phe, and p-X-Phe, where X is F, Cl, Br, NO.sub.2, OH or CH.sub.3 ; A.sup.4 is Ala, Val, Leu, Ile, Nle, or .alpha.-aminobutyric acid; A.sup.5 is Val, Ala, Leu, Ile, Nle, Thr, or .alpha.-aminobutyric acid; A.sup.6 is Gly, Sar, .beta.-Ala, or the D-isomer selected from Ala, N-methyl-Ala, Trp, and Nal; A.sup.7 is His, 1-methyl-His, 3-methyl-His, Lys, or .epsilon.-alkyl-Lys; A.sup.8 is Leu, Ile, Val, Nle, .alpha.-aminobutyric acid, Trp, Pro, Nal, Chx-Ala, Phe, or p-X-Phe, where X is F, Cl, Br, NO.sub.2, OH or CH.sub.3 ; A.sup.9 is Met, Met-oxide, Leu, Ile, Nle, .alpha.-aminobutyric acid, or Cys; each R.sub.1 and R.sub.2, independently, is H, C.sub.1-12 alkyl, C.sub.7-10 phenylalkyl, or COE.sub.1, where E.sub.1 is C.sub.1-20 alkyl, C.sub.3-20 alkenyl, C.sub.3-20 alkynyl, phenyl, 3,4-dihydroxyphenylalkyl, naphthyl, or C.sub.7-10 phenylalkyl; provided that when either R.sub.1 or R.sub.2 is COE.sub.1, the other must be H; and R.sub.3 is OH, NH.sub.2, C.sub.1-12 alkoxy, C.sub.7-10 phenylalkoxy, C.sub.11-20 naphthylalkoxy, C.sub.1-12 alkylamino, C.sub.7-10 phenylalkylamino, C.sub.11-20 naphthylalkylamino; or a pharmaceutically acceptable salt of such peptides.

Abstract translation: 本发明的特征在于线性治疗肽，其具有以下结构式：其中A1是D-α-芳香族氨基酸或D-α-被束缚氨基酸的 A2是Gln，His，1-甲基-He或3-甲基-He; A3是选自Nal，Trp，Phe和p-X-Phe的D-或L-异构体，其中X是F，Cl，Br，NO 2，OH或CH 3; A4是Ala，Val，Leu，Ile，Nle或α-氨基丁酸; A5是Val，Ala，Leu，Ile，Nle，Thr或α-氨基丁酸; A6是Gly，Sar，β-Ala或选自Ala，N-甲基-Ala，Trp和Nal的D-异构体; A7是His，1-甲基-He，3-甲基-His，Lys或ε-烷基-Ilu; A8是Leu，Ile，Val，Nle，α-氨基丁酸，Trp，Pro，Nal，Chx-Ala，Phe或p-X-Phe，其中X是F，Cl，Br，NO 2，OH或CH 3; A9是Met，Met-氧化物，Leu，Ile，Nle，α-氨基丁酸或Cys; 每个R1和R2独立地是H，C1-12烷基，C7-10苯基烷基或COE1，其中E1是C1-20烷基，C3-20烯基，C3-20炔基，苯基，3,4-二羟基苯基烷基，萘基 或C7-10苯基烷基; 条件是当R1或R2是COE1时，另一个必须是H; 并且R 3是OH，NH 2，C 1-12烷氧基，C 7-10苯基烷氧基，C 11-20萘基烷氧基，C 1-12烷基氨基，C 7-10苯基烷基氨基，C 11-20萘基烷基氨基; 或这些肽的药学上可接受的盐。

公开(公告)号：US5409837A

公开(公告)日：1995-04-25

申请号：US058052

申请日：1993-05-05

Applicant: Charles S. Levings, III ,  Ralph E. Dewey ,  Carl J. Braun

Inventor： Charles S. Levings, III ,  Ralph E. Dewey ,  Carl J. Braun

IPC: C07K14/415 ,  C12N15/65 ,  C12N15/82 ,  C12P21/06 ,  A61K35/78 ,  A61K35/80 ,  C07K15/00

CPC classification number: C07K14/415 ,  C12N15/65 ,  C12N15/8289 ,  Y10S435/849

Abstract: A unf. 13 protein and gene encoding it are disclosed which confer sensitivity to B. maydis T toxin and the insecticide methomyl, in cells carrying the gene and expressing the protein. Toxin sensitivity domains of the protein have been identified wherein a modification yields a toxin-insensitive product.

Abstract translation: 一个不 13蛋白和编码它的基因被公开，其在携带该基因并表达蛋白质的细胞中赋予对B. maydis T毒素和杀虫剂methomyl的敏感性。 已经鉴定了蛋白质的毒素敏感域，其中修饰产生毒素不敏感产物。

公开(公告)号：US5408041A

公开(公告)日：1995-04-18

申请号：US180572

申请日：1994-01-13

Applicant: Gregory R. Mundy ,  Gloria E. Gutierrez ,  Ian R. Garrett ,  Massimo Sabatini ,  Elzbieta Izbicka ,  Wilson Burgess ,  Gregg R. Crumley ,  Clarence C. Morse ,  Timothy R. Arnett

Inventor： Gregory R. Mundy ,  Gloria E. Gutierrez ,  Ian R. Garrett ,  Massimo Sabatini ,  Elzbieta Izbicka ,  Wilson Burgess ,  Gregg R. Crumley ,  Clarence C. Morse ,  Timothy R. Arnett

IPC: C12N15/09 ,  A61K35/32 ,  A61K38/00 ,  A61K38/22 ,  A61K39/395 ,  A61P3/00 ,  A61P43/00 ,  C07K1/16 ,  C07K1/20 ,  C07K1/22 ,  C07K14/51 ,  C07K14/65 ,  C07K16/00 ,  C07K16/22 ,  C12P21/02 ,  C07K1/00 ,  C07K3/00 ,  C07K15/00

CPC classification number: C07K14/65 ,  C07K14/51 ,  C07K16/22 ,  A61K38/00

Abstract: The present invention relates to the development of bone growth factors as therapeutics for the prevention and treatment of pathological conditions involving bone tissue. The present invention provides biologically active proteinaceous factors comprising polypeptides containing the amino acid sequence M-A-G-L-G-D-E-F-G-D, [SEQ ID NO: 1], (X) F E T L F G A/V E D V I/D A L Q F V C G D, [SEQ ID NO: 2], or A-Y-I-P-I-E-T-L-E-G-I/G-E-L-V-D/Q-T-G/L-Q-F, [SEQ ID NO: 3], or biologically active fragments or sequence analogues thereof. Among the biological properties of the proteinaceous materials of the present invention is the capability to promote the growth and/or differentiation of osteoblastic cells.

Abstract translation: 本发明涉及作为预防和治疗涉及骨组织的病理状况的治疗剂的骨生长因子的发展。 本发明提供包含含有氨基酸序列MAGLGDEFGD，[SEQ ID NO：1]，（X）FETLFGA / VEDVI / DALQFVCGD，[SEQ ID NO：2]或AYIPIETLEGI / GELVD / QTG / LQF的多肽的生物活性蛋白质因子 ，[SEQ ID NO：3]或其生物活性片段或序列类似物。 本发明的蛋白质材料的生物学特性是促进成骨细胞生长和/或分化的能力。

公开(公告)号：US5374431A

公开(公告)日：1994-12-20

申请号：US988754

申请日：1992-12-10

Applicant: Roy H. L. Pang ,  Charles M. Cohen ,  Peter C. Keck

Inventor： Roy H. L. Pang ,  Charles M. Cohen ,  Peter C. Keck

IPC: A61K38/00 ,  A61L24/00 ,  A61L24/10 ,  A61L27/22 ,  A61P43/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/00 ,  C07K14/485 ,  C07K14/495 ,  C07K14/52 ,  C07K14/575 ,  C07K14/65 ,  C12N1/21 ,  C12N15/09 ,  C12P21/02 ,  C07K15/00 ,  A61K37/02 ,  C07K13/00 ,  C08L89/00

CPC classification number: C07K14/001 ,  A61L24/106 ,  A61L27/227

Abstract: This invention pertains to a synthetic adhesive composition for use in aqueous environments. The composition comprises polypeptide chains having an .alpha.-helical structure in aqueous environments and capable of cohesive and adhesive interactions. The polypeptide chains comprise polar and apolar amino acids, the apolar and polar amino acids being arranged to define apolar and polar vertical spiraling stripes on the helix surface. The apolar stripes allow the polypeptide chains to aggregate into superhelical structures and the polar stripes allow interchain crosslinking within and between the superhelical structures.

Abstract translation: 本发明涉及用于水性环境的合成粘合剂组合物。 组合物包含在水性环境中具有α-螺旋结构并能够凝聚和粘合相互作用的多肽链。 多肽链包含极性和非极性氨基酸，非极性和极性氨基酸被布置成在螺旋表面上限定非极性和极性的垂直螺旋状条。 非极性条纹允许多肽链聚集成超螺旋结构，并且极性条纹允许在超螺旋结构内和之间的链间交联。

公开(公告)号：US5371190A

公开(公告)日：1994-12-06

申请号：US90902

申请日：1993-07-12

Applicant: Paul J. Carter ,  James A. Wells

Inventor： Paul J. Carter ,  James A. Wells

IPC: C11D3/386 ,  C12N9/54 ,  C12N9/56 ,  C12N15/10 ,  C12N15/31 ,  C12N15/52 ,  C12N15/75 ,  C07K15/00

CPC classification number: C12N15/52 ,  C11D3/386 ,  C12N15/102 ,  C12N15/75 ,  C12N9/54 ,  C12R1/07

Abstract: Novel enzyme mutants are disclosed which are derived from a precursor enzyme by replacing or modifying at least one catalytic functional group of an amino acid residue in a precursor enzyme. Such mutant enzymes have a catalytic preference for substrates which provide the replaced or modified catalytic group or its equivalent such that the substrate together with the enzyme mutant assists in its own catalysis.

Abstract translation: 公开了通过置换或修饰前体酶中氨基酸残基的至少一个催化官能团而衍生自前体酶的新型酶突变体。 这样的突变酶对提供替代或修饰的催化基团或其等同物的底物具有催化倾向，使得底物与酶突变体一起有助于其自身的催化。